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Background: There is a need to discover novel chemical compounds that will inhibit the pathological process of epileptogenesis
(i.e. agents that will prevent the long-term formation of an active seizure focus following a brain insult). The goal of this paper
is to identify a bioassay of value in drug design when screening new chemical entities as putative antiepileptogenic agents.
Methods: We focused on two models: the pilocarpine chronic seizure model of spontaneous recurrent seizures (SRSs) and a
chronic subdural haematoma model of SRSs. Both models were evaluated using more than 20 Sprague–Dawley rats for each
model.
Results: In the pilocarpine-induced model of SRSs, 80% of animals went on to develop SRSs when the dose of pilocarpine was
380 mg/kg i.p. In 50 animals that developed SRSs, the average number of seizures per 15 days of observation was 3.8 seizures
with a range of 2–23 seizures per 15-day period. The chronic subdural model was inefficient in producing SRSs.
Conclusions: A pilocarpine-induced SRS model of epilepsy affords a reliable model of epileptogenesis suitable for evaluating
new chemical entities as putative antiepileptogenics.
© 2003 BEA Trading Ltd. Published by Elsevier Ltd. All rights reserved.
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INTRODUCTION
There is a need to discover novel chemical compounds
that will inhibit the pathological process of epilep-
togenesis (i.e. agents that will prevent the long-term
formation of an active seizure focus following a brain
insult). Epileptogenesis is a slow, insidious biochemi-
cal and morphological process whereby normal brain
is transformed (after a ‘latency period’) into patho-
logically excitable neural tissue that is susceptible
to spontaneous recurrent seizures (SRSs)1, 2. Most
therapies currently available for the treatment of
epilepsy do not possess antiepileptogenic properties.
Various controlled studies on the efficacy of tradi-
tional anticonvulsant drugs as prophylactic agents
against epilepsy have failed to show protective effects
for agents such as phenytoin or carbamazepine3, 4.
These currently available anticonvulsant medications
do not specifically target epileptogenesis, but rather
seek to inhibit ictogenesis—the rapidly propagat-
ing electrical and chemical event whereby aberrant
electrical hyper-excitability spreads from the seizure
focus giving rise to the clinical manifestations of a
seizure2, 5, 6. The market for anti-ictogenic (anticon-
vulsant, anti-seizure) agents has been well served
over the past century with traditional agents such as
phenobarbital, phenytoin and carbamazepine and with
newer generation medications such as lamotrigine.
It is a neuropharmacologic priority that the design
strategy must now change from anti-seizure agents to
antiepileptogenic agents.
Central to a comprehensive programme targeting
the discovery of antiepileptogenic agents is the need
for an appropriate animal model. This model not only
must accurately reflect the biology of epileptogene-
sis, but also must be useful for the facile screening
of new chemical entities for potential bioactivity.
Current widely used assays, such as the maximal
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electroshock (MES) model and the pentylenetetrazol
(ScMet) model (and other related chemoconvulsant
assays) are models of seizures, rather than models of
epileptogenesis. Although kindling has been put for-
ward as a model for epileptogenesis, the applicability
of kindling as a procedure for identifying potential
therapeutics for epilepsy has been debated7, 8. Ac-
cordingly, there is a continuing need for relevant
models of epileptogenesis that can be used in the
screening of new chemical entities.
The goal of this paper is to identify a bioassay of
potential value in drug design and discovery when
screening new chemical entities as putative antiepilep-
togenic agents. The drug design/medicinal chemistry
literature does not currently employ an ‘accepted’
model of epileptogenesis. Accordingly, we describe
our attempts to identify an in vivo model of epilep-
togenesis that reliably produces SRSs in an experi-
mental model that also could permit the screening of
test molecules for potential antiepileptogenic activity.
After preliminary evaluation of several models, we
focused on two models for potential development:
the pilocarpine chronic seizure model (adapted from
Mello et al.9, 10) and a chronic subdural haematoma
model (adapted from Willmore and co-workers11, 12).
METHODS AND MATERIALS
The pilocarpine chronic seizure model of
spontaneous recurrent seizures
As a first step it was crucial that the model be imple-
mented in a manner that would enable accuracy and
reproducibility. Initial experiments were performed
using groups of 10 rats. On day 1, a group of 10 male
Sprague–Dawley rats (175–200 g, Charles River) was
given methylscopolamine (1 mg/kg i.p.) to minimise
the peripheral effects of pilocarpine. Thirty minutes
later, the animals were injected with pilocarpine
(380 mg/kg i.p., Aldrich Chemical Co.). Approxi-
mately 15 minutes later, 80% of the rats entered a
state of convulsive status epilepticus. Animals that
did not undergo continuous seizure activity were not
used any further in the study. Initially, the animals
typically exhibited ear twitching, head jerking and
body rearing, followed by several minutes in which
this behaviour diminished slightly; then the body
movements started again and a constant seizure state
persisted for hours. If the animal was able to sustain
the continuous seizure activity while remaining on
its feet (moderate severity) then the status epilepti-
cus was allowed to last for 3 hours. However, if the
seizure severity was severe and the animal was ly-
ing on its side, then the seizure was terminated after
2 hours. In our experience, animals that underwent a
severe seizure for 3 hours did not survive the experi-
ment. The mortality rate during the status epilepticus
period was 20%. The behavioural aspects of the
seizures were stopped at the desired time (2 hours for
severe seizures; 3 hours for moderate severity) by the
administration of diazepam (4 mg/kg i.p.). This injec-
tion stopped the seizure activity after an average of
2.8 minutes. Following the status epilepticus episode,
the hydration level of the animals was supported by
the administration of 20% sucrose Gatorade solution
(2.5 ml, p.o.) and Ringer’s lactate solution (5 ml i.p.)
once a day for 7 days. Additionally, a portion of the
rat chow pellets was ground into a paste using water.
The animals were weighed each day. A 20% body
weight loss was typical following the status epilepti-
cus; normal eating patterns with evidence of weight
was typically recovered by day 3.
Rats were placed individually in clear Plexiglas
cages; food and water were provided ad libitum. The
light/dark cycle was maintained at 12 hours/12 hours.
On day 21, the cages were placed in the videotaping
room. The animals were placed in front of video cam-
era stations and were videotaped for 8 hours/day, 5
days/week for 8 weeks. Six cages were placed in each
taping station with a contrasting dark background
behind the cages. The number of seizures was deter-
mined by individuals viewing the videotapes. Quality
control and quality assurance methods were put in
place to verify the seizure count data. Every tenth
videotape produced was double-viewed to check the
agreement between the viewers.
Following 2 months of videotaping the animals
were euthanised on day 81. In order to prepare for
histological analysis of the brain two perfusion solu-
tions were prepared containing: (1) 0.37% sulphide
solution (pH 7.2; 11.7 g Na2S·9H2O plus 11.9 g
NaH2PO4·H2O made up to 1000 ml; (2) 10% neutral
buffered formalin (NBF; 90 ml of 37% formaldehyde,
3.6 g NaH2PO4·H2O and 5.85 g Na2HPO4·7H2O)
dissolved in 810 ml of distilled water13. The ani-
mals were anaesthetised using sodium pentobarbital
(65 mg/kg i.p.) and the thoracic cavity was exposed.
The descending aorta was tied off with a ligature.
A needle containing the sulphide perfusion solution
was then placed into the left ventricle and clamped
into place. Another needle was rinsed with heparin
(10 000 USP units/ml) and used to withdraw 5 ml
of blood from the heart. Using scissors a nick was
then placed in the right atrium. The 60 ml sulphide
perfusion solution was pushed through followed im-
mediately by 60 ml of neutral buffer formalin. The
heart, lungs, liver, kidneys and brain were then re-
moved. The brain was placed in a vial and covered
with neutral buffer formalin. The other organs were
weighed and measured and a gross examination was
performed.
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As discussed in Section ‘RESULTS’, 8 of 10 rats
developed SRSs. Accordingly, additional refining
experiments were performed. (i) We experimented
with varying doses of pilocarpine. Higher doses of
pilocarpine (400 mg/kg) produced unacceptably high
mortality (6/10 mortality); lower doses of pilocarpine
(350 mg/kg) produced unacceptably low rates of SRS
development (4/10 developed recurrent seizures). (ii)
To ensure that the behavioural manifestations of the
seizure corresponded with electrographic seizures, a
subset of 10 rats had EEG’s recorded. All rats with
SRSs showed generalised spike and sharply contoured
epileptiform discharges during clinically apparent
seizure activity manifesting as whisker twitching,
tail extension, body twisting, piloerection, and body
rearing with pedalling of the forepaws. (iii) To en-
sure that the behavioural manifestations of this model
correspond with discernible pathology, a subset of 10
rats had post-mortem brain histology examinations
performed on cortical (frontal, parietal, temporal and
occipital), subcortical and brainstem tissue.
In accord with previous studies by Mello and
co-workers10, 13–16, the SRS model produced neuronal
loss and damage in the hippocampus and adjacent
limbic structures, paralleling temporal lobe epilepsy.
To ensure that the SRS model did not produce sys-
temic non-CNS pathology which could be inappro-
priately ascribed to a candidate chemical compound
undergoing screening (thereby limiting its promotion
as a drug candidate), all animals that were videotaped
had post-mortem examinations of their organ systems.
Pathological examination of heart, lungs, kidneys,
liver, stomach, and intestines showed no evidence of
gross pathology.
The chronic subdural haematoma model of
spontaneous recurrent seizures
Male Sprague–Dawley rats were also used for this
model. Each rat was anaesthetised with sodium pen-
tobarbital (65 mg/kg i.p.). The underside of one of the
rear legs was shaved. A small incision was made to
expose the femoral vein and artery. A heparin solution
(0.05 ml, 1000 units/ml) was drawn up into a syringe
just prior to blood collection. Blood was drawn into
the needle (0.3 ml total of heparin solution and blood)
by inserting a 25 G needle into the femoral vein. Af-
ter removing the needle, pressure was applied to the
injection site to stop any bleeding. The incision was
sutured. Next, the animal was placed in a stereotac-
tic head frame. A rectal thermostat with an attached
heat lamp was set up to ensure maintenance of body
temperature. A midline incision was made through the
scalp and the skull was exposed. The skull plate and
meninges were removed over target area of the left
temporal lobe. Then, 10µl of venous blood/heparin
(previously drawn from the femoral vein) was slowly
injected 1.0 mm into the temporal lobe cortex over
10 minutes. The skull plate was then replaced, the dura
was not repaired, and the scalp was closed. The ani-
mal was removed from the head frame, and allowed
to recover. Two weeks later the animal was placed
in a video camera recording station. The rats were
videotaped 8 hours/day, 5 days/week for 6 weeks. The
number of seizures was counted from the videotapes.
On day 56, each rate was anaesthetised (with sodium
pentobarbital), and then euthanised by cardiac punc-
ture. A fixative solution was perfused to prepare the
brain for histological analysis (as discussed above for
chronic pilocarpine model).
The brains were removed and stored in paraffin. The
organs were examined for abnormalities. Pathological
examination of the brain confirmed that blood had
been injected to a depth of 1.0 mm into the cortex with
the formation of an adjacent haematoma.
As discussed in Section ‘RESULTS’, only 1/10 rats
developed spontaneous seizures. In an attempt to im-
prove this frequency of epilepsy, a number of modifi-
cations were pursued in groups of four rats. Another
series of experiments was performed in which a for-
eign body (blood soaked surgical sponge) was left on
the cortex of the brain over the point of injection into
the cortex. None of these animals developed seizures.
Alternatively, rather than injecting the blood into the
cortex, an attempt was made merely to raise a subdural
haematoma on the surface of the sensorimotor cortex
without insertion of blood into the parenchyma of the
brain. None of these animals developed seizures.
RESULTS
In the pilocarpine induced model of SRSs, 80% of
animals went on to develop SRSs when the dose of
pilocarpine was 380 mg/kg i.p. In 50 animals that
developed SRSs, the average number of seizures per
15 days of observation was 3.8 seizures with a range
of 2–23 seizures per 15 day period. When the pilo-
carpine dose was raised to 400 mg/kg, the mortality
rate was 80% (8/10); when the pilocarpine dose was
lowered to 350 mg/kg, the number of animals devel-
oping SRSs fell to 40% (4/10). Pathological exami-
nation of the brains of animals that developed SRSs
revealed neuronal loss and damage in the hippocam-
pus and related limbic structures, paralleling temporal
lobe epilepsy. Electroencephalographic recordings of
animals with SRSs revealed epileptiform discharges
during clinically apparent seizure activity manifesting
as whisker twitching, tail extension, body twisting,
piloerection, and body rearing with pedalling of the
forepaws.
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In the subdural haematoma induced model of SRSs,
10% of animals went on the develop SRSs. This one
animal only demonstrated one seizure during the en-
tire observation period. When a foreign body was in-
serted (blood soaked sponge) 0/4 animals developed
seizures. When the haematoma was injected subdu-
rally without blood injection into cortex, 0/4 animals
developed seizures.
DISCUSSION
Since Merritt and Putnam’s historic discovery of
phenytoin in the late 1930s, there have been many
models put forth to screen novel chemicals as potential
agents for the treatment of epilepsy (e.g. MES, ScMet,
strychnine, bicuculline, picrotoxin, allylglycine, iso-
niazid, 3-mercaptoproprionate, beta-carboline, peni-
cillin, tungstic acid)17. Virtually all of these models
have been models of seizures (ictogenesis) and not
models of chronic epileptogenesis. Although models
such as the MES and ScMet assays have been used
extensively, they have been useful in finding anti-
convulsants, not antiepileptogenics. Since the need
for antiepileptogenics is emerging as a neuropharma-
cologic priority, the need for an appropriate animal
model with which to discover antiepileptogenics is
also a priority.
Whether kindling is such an animal model is open
to debate. As an experimental technique, kindling has
been available for many years; however, it has failed to
yield an antiepileptogenic drug. Kindling refers to the
process whereby a subthreshold stimulus (usually a
focal electrical stimulation of a limbic or cortical
structure) repeated over days or weeks becomes a
convulsant stimulus18. Kindling is a relatively time
consuming procedure as it requires the chronic im-
plantation of stimulating electrodes in the amygdala,
hippocampus, or cortex, and daily electrical stimula-
tion with scoring of either the after-discharge dura-
tion or of the motor seizure response. Furthermore,
the relationship between kindling and spontaneous
human epilepsy remains controversial. Because the
kindled seizure is evoked rather than spontaneous
and lacks a definable latent period, kindling is not
considered to be an ideal model of epileptogenesis19.
Another criticism of the kindling model as an assay
with which to identify a potential antiepileptogenic
compound is that the test substance is administered
before the kindling stimulation. Finally, even though
a drug might be found to retard the kindling process,
the fully kindled rat does not normally exhibit sponta-
neous seizures; therefore, it is impossible to conclude
whether the ability of the drug to block kindling
will inhibit the fundamental mechanistic processes of
epileptogenesis19. Whether kindling is an appropriate
animal model with which to identify antiepilepto-
genic compounds remains uncertain; therefore, the
search for a possible alternative persists.
In attempting to identify an alternative to the kin-
dling model for drug molecule screening, a number of
possibilities were considered. As stated above, most
current animal models are models of seizures rather
than models of epileptogenesis. In a recent review
of animal models of epileptogenesis, White discusses
three general classes of models, other than kindling:
status epilepticus (e.g. pilocarpine-induced), brain in-
jury (e.g. subdural haematoma or FeCl2 induced, fluid
percussion, cortical undercut), and age-specific mod-
els (e.g. neonatal hypoxia, neonatal hyperthermia)19.
In addition to these models, other workers have de-
scribed the onset of seizures following focal applica-
tion of metal salts, in particular aluminum, in monkey
and cat17. These various models all exhibit strengths
and weaknesses. For instance, the fluid percussion
model does not produce spontaneous seizures. Like-
wise, the neonatal hypoxia and hyperthermia models
also do not yield spontaneous seizures. The use of
metallic salts may be more relevant to ictogenesis than
to epileptogenesis. Accordingly, we elected to evalu-
ate both a status epilepticus (pilocarpine-induced) and
a brain injury (subdural haematoma) model.
The adaptation of the SRS model of epileptogene-
sis as presented in this study is a model that strives to
represent the human situation in which an antiepilep-
togenic medication would be given following a head
injury. The status epilepticus model is analogous to
recurrent seizures after prolonged febrile convulsions;
the subdural haematoma model represents the patho-
genesis of post-traumatic epilepsy. These SRS models
thus have biological and clinical relevance.
In the comparison of the status epilepticus versus
chronic subdural models presented in this study, the
status epilepticus model was better. The chronic sub-
dural model produced few if any seizures. The status
epilepticus model produced numerous spontaneous
seizures with high reliability after an appropriate
latent period. The seizures correlated with EEG ab-
normalities and with histopathological changes. If
a test compound was administered after the status
epilepticus, this model could be used to evaluate new
chemical entities as putative antiepileptogenic agents.
Despite its obvious strengths, the pilocarpine-indu-
ced SRS model also has limitations from the perspec-
tive of being an assay for screening new chemical
entities. Although the SRS model is biologically rel-
evant, the time requirements and the large amount
of labour involved in the videotape viewing is a ma-
jor drawback of this screening program. Nevertheless,
this assay does provide a model of epileptogenesis
rather than merely a model of seizures, and could be
used to evaluate novel compounds. The ultimate suc-
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cess of the pilocarpine induced SRS model to identify
new antiepileptogenic agents must await its successful
application.
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